Exhibit 99.1


Contact:
McDavid Stilwell
Manager, Corporate Communications and Financial Analysis
GTx, Inc.
(901)523-9700


             GTx Announces Delay of Public Offering of Common Stock


Memphis, Tenn., September 23, 2005 -- GTx, Inc. (Nasdaq: GTXI), the Men's Health
Biotech Company, announced today that it is delaying its proposed public
offering of 5,000,000 shares of common stock due to market conditions.

This press release does not constitute an offer to sell or a solicitation of an
offer to buy any securities. The offering would be made solely by means of a
prospectus and an accompanying preliminary prospectus supplement. These
securities may not be sold nor may offers to buy be accepted prior to the time
that the prospectus supplement and base prospectus are delivered in final form.
There will not be any sale of these securities in any state or jurisdiction in
which such offer, solicitation or sale would be unlawful prior to registration
or qualification under the securities laws of any such state or jurisdiction.


About GTx

GTx is a biopharmaceutical company dedicated to the discovery, development and
commercialization of therapeutics for cancer and serious conditions related to
men's health. GTx's lead drug discovery and development programs are focused on
small molecules that selectively modulate the effects of estrogens and
androgens, two essential classes of hormones. GTx, headquartered in Memphis,
Tenn., currently has four clinical programs.